CD40–TRAF6 interaction

The CD40–TRAF6 interaction refers to the specific binding of the adaptor protein TRAF6 (Tumor necrosis factor receptor-associated factor 6) to a proximal cytoplasmic domain of the CD40 receptor, a member of the TNF receptor superfamily highly expressed on antigen-presenting cells such as B cells, dendritic cells, and macrophages[1][3][4]. Upon engagement by its ligand CD40L (CD154), CD40 recruits TRAF6 (distinct from TRAF2/3/5, which bind to separate domains), resulting in activation of downstream pro-inflammatory signaling cascades including NF-κB and MAPK pathways that regulate immune cell activation, cytokine release, and the migration and polarization of monocytes and macrophages[1][2][3][5][6]. This interaction plays a pivotal role in the pathogenesis of chronic inflammation, atherosclerosis, metabolic syndrome, and neuroinflammatory diseases by promoting the recruitment and differentiation of pro-inflammatory monocytes (Ly6Chigh), skewing macrophages toward a pro-inflammatory (M1-like) phenotype, and facilitating leukocyte infiltration into inflamed tissues[1][2][5]. Targeted inhibition of the CD40–TRAF6 interaction by small molecules (such as 6877002) reduces pathological inflammation and monocyte migration, with potential therapeutic applications in cardiovascular disease, neuroinflammation, and obesity-related metabolic dysfunction[1][5][6]. Blockade of this pathway generally preserves protective immune responses mediated by other CD40–TRAF interactions, suggesting possible selectivity in modulating immunity[5].

Other names

CD40–TRAF6 signaling axisCD40–Tumor necrosis factor receptor-associated factor 6 interaction

Small molecule inhibition of CD40–TRAF6 binding disrupts downstream inflammatory signaling and leukocyte trafficking[1][5][6]; peptide inhibitors that mimic TRAF6-binding motifs competitively block CD40–TRAF6 recruitment[3].